HOOKIPA PHARMA INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 24 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-12-17: Reporting owner Matushansky Igor; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-12-17: Reporting owner Matushansky Igor; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-12-17: Reporting owner Matushansky Igor; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-12-16: Reporting owner Matushansky Igor; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-12-17 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −31,656 8,079 owned after | $0.10 exercise price | 2020-12-18 | |
| 2020-12-17 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,367 14,208 owned after | $0.10 exercise price | 2020-12-18 | |
| 2020-12-17 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,965 7,669 owned after | $0.10 exercise price | 2020-12-18 | |
| 2020-12-16 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −640 39,735 owned after | $0.10 exercise price | 2020-12-18 | |
| 2020-12-15 | Soria Jean-Charles Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,200 19,200 owned after | $11.97 exercise price | 2020-12-17 | |
| 2020-06-18 | van Deventer Sander Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $11.45 exercise price | 2020-06-19 | |
| 2020-06-18 | Kaufman David Ross Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $11.45 exercise price | 2020-06-19 | |
| 2020-06-18 | Kelly Michael Aaron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $11.45 exercise price | 2020-06-19 | |
| 2020-06-18 | van de Winkel Jan Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,200 19,200 owned after | $11.45 exercise price | 2020-06-19 | |
| 2020-06-18 | Lengauer Christoph Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $11.45 exercise price | 2020-06-19 | |
| 2020-06-18 | O'Neill Julie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $11.45 exercise price | 2020-06-19 | |
| 2020-06-18 | Seghezzi Graziano Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $11.45 exercise price | 2020-06-19 | |
| 2020-04-20 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +65,200 0 owned after | $8.03 exercise price | 2020-04-24 | |
| 2020-04-20 | Necina Roman Officer (Chief Technology Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 0 owned after | $8.03 exercise price | 2020-04-24 | |
| 2020-04-20 | Orlinger Klaus Officer (EVP, Research) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 0 owned after | $8.03 exercise price | 2020-04-24 | |
| 2020-04-20 | Aldag Jorn Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 0 owned after | $8.03 exercise price | 2020-04-24 | |
| 2020-04-20 | Kandera Reinhard Director, Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +77,400 0 owned after | $8.03 exercise price | 2020-04-24 | |
| 2020-01-23 | Lilja Anders Officer (Sr. VP, Technical Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,075 0 owned after | $0.10 exercise price | 2020-01-27 | |
| 2020-01-23 | Lilja Anders Officer (Sr. VP, Technical Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,568 13,098 owned after | $0.10 exercise price | 2020-01-27 | |
| 2020-01-21 | Orlinger Klaus Officer (Sr. VP, Research) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,789 7,741 owned after | $0.10 exercise price | 2020-01-21 | |
| 2020-01-16 | Orlinger Klaus Officer (Sr. VP, Research) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,140 0 owned after | $0.10 exercise price | 2020-01-21 | |
| 2020-01-16 | Orlinger Klaus Officer (Sr. VP, Research) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −571 14,530 owned after | $0.10 exercise price | 2020-01-21 | |
| 2020-01-14 | Orlinger Klaus Officer (Sr. VP, Research) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,358 0 owned after | $0.10 exercise price | 2020-01-16 | |
| 2020-01-14 | Orlinger Klaus Officer (Sr. VP, Research) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,142 1,140 owned after | $0.10 exercise price | 2020-01-16 |